|  | 


Covid-19: the vaccine may be available in pharmacies


Depending on the number of coronavirus disease (Covid-19) vaccines available for the second quarter of 2021, experts making decisions related to vaccines are considering making the vaccines available for private use for those who can even afford when the vulnerable population is being inoculated. It is expected to start early next year once a candidate is finalized.

Prices may be subsidized in private markets, said a team expert, requesting anonymity. However, the move will be subject to the granting of regulatory approvals to candidates for the Covid-19 vaccine.

“This is something that was also done with the flu vaccine; those who can pay can access the vaccine in a private (market) with certain passengers, ”said another senior government official, who also spoke on condition of anonymity. It is also part of the vaccine delivery process.

The government had previously announced that India aims to vaccinate at least 300 million high-risk people by July next year. He is currently drafting a beneficiary list that includes approximately 30 million frontline and healthcare workers for the first phase.

Currently, clinical trial data for two candidate vaccines, Pfizer-BioNTech and Oxford-AstraZeneca, manufactured in India by the Serum Institute of India, are being reviewed by the Central Drugs Standard Control Organization (CDSCO).

The three vaccine candidates whose emergency use authorization (US) applications are before the national drug regulator are: Pfizer-BioNTech, Serum Institute of India’s Oxford-AstraZeneca, and Bharat Biotech-Indian Council of Medical Research.

The director of the Indian Institute of Medical Sciences (AIIMS), Delhi, said that USA is likely to be awarded later this year or early next.

“As things appear at the moment, the necessary regulatory approvals are likely to come late this year or early next,” Dr. Guleria said in an interview with a television channel on Thursday.

“For the Oxford-AstraZeneca vaccine candidate, there is not only the data from the Serum India trial, but also the data from the UK trials of AstraZeneca,” he added.

While Pfizer had not come forward to present its case at the last subject matter expert committee (SEC) meeting on Dec. 9, experts had sought additional data from the other two companies that had applied for the USA-Serum Institute and Bharat. Biotech.

Serum submitted the data on Monday, and Pfizer is also ready to make its case and has requested a new date from the drug regulator. The regulator is examining the data before setting a date for a SEC to convene.

However, Bharat Biotech has not yet returned to CDSCO with new data.

Several Covid-19 vaccine candidates around the world are currently in advanced phase 3 clinical trials to establish the efficacy of the vaccine candidate. Emergency use authorization is generally based on preliminary data from phase 3. For market use authorization, regulators look for comprehensive test data.

Original source